ABLIM3 Activators
ABLIM3, an actin-binding protein, is intricately involved in the regulation of cytoskeletal dynamics and is subject to activation through various signaling pathways. Activation of adenylyl cyclase leads to an increase in intracellular cAMP levels, which in turn activates protein kinase A. The phosphorylation cascade mediated by PKA is capable of modifying proteins that participate in actin filament dynamics, thus influencing the activity of ABLIM3. Additionally, activation of protein kinase C through specific diacylglycerol analogs can lead to phosphorylation events within the actin cytoskeleton, affecting ABLIM3's associated structures and potentially increasing its activity. Inhibition of protein phosphatases can also maintain the phosphorylation state of components within actin dynamics pathways, while modulators of calcium signaling can activate calmodulin-dependent kinases, both of which are likely to impact ABLIM3's role in cytoskeletal organization due to its sensitivity to protein phosphorylation states and calcium-mediated signaling.
Moreover, agents that directly modulate the actin cytoskeleton, such as actin filament stabilizers, can increase ABLIM3's activity by promoting polymerization and stabilization of actin structures to which ABLIM3 binds. Conversely, agents that disrupt actin polymerization may alter the dynamics of actin filaments and, as a result, can affect the functional state of ABLIM3. Since ABLIM3's activity is closely tied to its ability to bind to actin, changes in the polymerization state of actin can either facilitate or hinder the binding efficiency and the functional role of ABLIM3. Furthermore, the Rho family of GTPases plays a pivotal role in the regulation of the actin cytoskeleton. Activators of these GTPases promote the formation of stress fibers, thereby potentially influencing the function of ABLIM3 through altered cytoskeletal architecture.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC), which can phosphorylate substrates involved in actin filament organization, potentially increasing ABLIM3 activity, which is associated with actin binding and cytoskeletal organization. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Inhibits protein phosphatases 1 and 2A, maintaining phosphorylation states of proteins within actin dynamics pathways, thus potentially enhancing ABLIM3 activity by preventing dephosphorylation of proteins within these pathways. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Increases intracellular calcium levels, which can activate calmodulin-dependent kinases, potentially enhancing ABLIM3 activity due to its role in actin cytoskeletal dynamics which are influenced by calcium signaling. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $33.00 $77.00 $120.00 | 14 | |
Modulates sphingosine-1-phosphate receptors, resulting in actin cytoskeletal rearrangements, which may indirectly lead to increased ABLIM3 activity due to its role in actin binding and cytoskeletal organization. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Stabilizes actin filaments and promotes actin polymerization, potentially increasing ABLIM3 activity as it is implicated in binding to actin structures. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Binds to the barbed ends of actin filaments, preventing further polymerization and leading to an altered actin dynamics, indirectly enhancing ABLIM3 activity due to its involvement in actin cytoskeletal organization. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits Rho-associated protein kinase (ROCK), leading to changes in actin cytoskeleton dynamics that could enhance ABLIM3 activity, given its cytoskeletal association. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits glycogen synthase kinase-3 (GSK-3), which may result in altered cytoskeletal dynamics and potentially enhance ABLIM3 activity due to its role in cytoskeletal regulation. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Inhibits myosin II ATPase activity, affecting myosin-driven actin cytoskeleton functions, potentially enhancing ABLIM3 activity due to its association with actin dynamics. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase (MLCK), which may lead to changes in actin-myosin interactions potentially enhancing ABLIM3's role in actin cytoskeletal organization. | ||||||